CRISPR Highlights Potential for Correcting Parkinson’s Disease-Associated Genes
Background
A review has examined the potential use of CRISPR gene editing to create disease models and explore therapeutic strategies for Parkinson’s disease. This literature review examines relevant technologies and research models; it is not a study demonstrating the therapeutic effects of gene correction in patients.
Parkinson’s disease involves the progressive loss of dopamine-producing neurons in the brain’s substantia nigra, with motor and non-motor symptoms. The review starts from the lack of effective treatments that stop or reverse disease progression, beyond treatments for symptoms. SNCA, LRRK2, and PINK1 are major disease-associated genes discussed in the review, but variants in these genes should not be generalized as the cause of all Parkinson’s disease.
Key findings
The review examines the mechanisms of CRISPR-Cas9, prime editing, and base editing and their applications in Parkinson’s disease research. It considers strategies to correct Parkinson’s disease-associated variants or regulate pathogenic gene expression. However, the provided abstract contains no numerical data for assessing gene-specific correction success rates or accuracy, making it difficult to conclude that precise correction of the variants in question has been established with these technologies.
Research models generated using CRISPR include isogenic cell lines, transgenic animals, and induced pluripotent stem cell (iPSC) models. The review explains the roles these models play in elucidating disease pathways and identifying new therapeutic targets. The abstract presents neither results showing faster model generation nor comparisons of generation times with conventional methods.
Implications and outlook
CRISPR-based models could serve as research tools for understanding Parkinson’s disease mechanisms and exploring therapeutic targets. The review also discusses the potential of neuroprotective strategies targeting processes such as mitochondrial dysfunction.
The potential uses of research models must be distinguished from therapeutic effects in patients. Although the authors discuss challenges to clinical translation, the abstract alone makes it difficult to assess specific experimental conditions or the limitations of clinical application. It also presents no results showing that disease progression has been suppressed or reversed in patients.
Related information is available in the Neurochemistry International review abstract.
Parkinson's disease (PD) manifests with both motor and non-motor symptoms due to the progressive loss of dopamine-producing neurons in the substantia nigra. While symptomatic treatments show promise, there remains no effective therapy to stop or reverse disease progression. Genes such as SNCA, LRRK2, and PINK1 are pivotal in PD etiology due to their mutations driving both familial and sporadic forms of the disease. The CRISPR-Cas9 system, a revolutionary genome-editing tool, offers precise genetic modification capabilities crucial for advancing PD research and therapy. Recent studies emphasize the efficacy and precision of prime editing and base editing techniques in gene modification within PD contexts. This review synthesizes recent advancements in utilizing CRISPR to develop PD models, focusing on their roles in elucidating disease pathways and discovering new therapeutic avenues. These models encompass isogenic cell lines, transgenic animals, and induced pluripotent stem cells (iPSCs). The review underscores the potential of CRISPR-based approaches to address PD-related mutations, regulate pathogenic gene expression, and develop neuroprotective strategies targeting critical processes like mitochondrial dysfunction. Additionally, it critically assesses the transformative potential and challenges associated with translating CRISPR technologies into clinical applications for PD treatment.
The practical significance of this review lies in examining gene correction as a tool for Parkinson’s disease research models and therapeutic target discovery. Researchers can consider using CRISPR-based cell, animal, and iPSC models to investigate disease pathways and identify targets for subsequent studies. Neuroprotective strategies targeting mitochondrial dysfunction are also presented as an area for exploration. However, the provided abstract reports neither model-specific performance nor efficacy in patients, so there is insufficient evidence to establish the superiority of a particular editing method or to treat suppression or reversal of disease progression as an established expected benefit.